UDP-Glucuronosyltransferase (UGT) Detection and Activity Profiling

Comprehensive UDP-Glucuronosyltransferase (UGT) Detection and Activity Profiling for Drug Metabolism, Toxicology, and Clinical Research

UDP-glucuronosyltransferases (UGTs) are a family of key phase II drug-metabolizing enzymes that catalyse the conjugation of glucuronic acid to a wide array of endogenous and exogenous compounds, including bilirubin, steroids, and numerous drugs. This glucuronidation reaction generally increases the water solubility of the substrates, facilitating their elimination via bile and urine. Given their central role in drug clearance, detoxification, and the regulation of essential physiological molecules, the accurate and comprehensive detection of UGT enzymes—at the levels of activity, protein abundance, and gene expression—is indispensable for preclinical drug development, pharmacokinetic profiling, toxicity assessment, and clinical pharmacogenetics. Our specialised detection platform offers a fully validated suite of biochemical and molecular assays tailored to UGT isoforms, delivering high-precision, actionable data that empower clients to optimise drug candidates, evaluate drug-drug interaction risks, and advance personalised medicine.

Understanding the Client's Need for UGT Analysis

Clients seeking UGT detection services are driven by a range of critical objectives. In drug discovery and development, the primary need is to characterise the glucuronidation clearance of new chemical entities (NCEs), to identify the specific UGT isoforms responsible for their metabolism, and to assess the potential for clinically relevant drug-drug interactions (DDIs). In toxicology and safety assessment, quantifying UGT activity in hepatic and extrahepatic tissues (e.g., intestine, kidney) helps to predict the accumulation of toxic compounds and the risk of hyperbilirubinemia. In clinical research and pharmacogenetics, measuring UGT activity or protein levels in patient-derived samples (e.g., liver microsomes, peripheral blood mononuclear cells) supports the study of inter-individual variability in drug response and the evaluation of genetic polymorphisms. In quality control of biological reagents, verifying the activity of UGT enzymes used in in vitro assays (e.g., recombinant UGT supersomes, human liver microsomes) is essential to ensure batch-to-batch consistency. In regulatory submissions, comprehensive data on UGT-mediated metabolism and inhibition are often required for IND and NDA filings. Our service is architected to address these diverse needs with a flexible, ISO 17025-accredited analytical framework that adapts to the specific enzyme source (recombinant, tissue microsomes, primary cells), substrate type, and client's regulatory context.

Integrated Analytical Platform for Holistic UGT Characterisation

Our analytical platform comprises four interconnected modules that collectively deliver a complete functional and molecular profile of any UGT sample. The Activity Profiling Module employs well-validated, isoform-specific assays using fluorogenic substrates (e.g., 4-methylumbelliferone, resorufin, or 7-hydroxycoumarin) or LC-MS/MS-based quantitation of the glucuronidated products of probe substrates (e.g., bilirubin, testosterone, estradiol, SN-38, propofol). We determine Michaelis-Menten parameters (K_m, V_max, intrinsic clearance) and inhibition constants (IC₅₀, K_i) with precision within ±3% RSD and a limit of detection (LOD) as low as 0.01 pmol/min/mg protein. For high-throughput screening, we offer a fluorescent microplate assay with a Z’-factor > 0.7. The Protein Quantitation Module uses sensitive ELISA with isoform-specific monoclonal antibodies (e.g., anti-UGT1A1, 1A6, 2B7, 2B15), providing LOQs of 0.1 ng/mg of total microsomal protein and inter-assay precision < 5%. For absolute quantitation without antibodies, we use LC-MS/MS-based targeted proteomics (PRM) with stable isotope-labelled peptide standards, achieving LOQs in the low fmol/mg range and enabling the simultaneous quantitation of multiple UGT isoforms in a single run. The Inhibition and Drug Interaction Module evaluates the effect of test compounds on a panel of major UGT isoforms (1A1, 1A3, 1A4, 1A6, 1A9, 2B7, 2B15, 2B17) using our validated probe substrate assays. We provide IC₅₀ values, mechanism-based inactivation parameters (k_inact, K_I), and time-dependent inhibition profiles, using non-linear regression with 95% confidence intervals. The Gene Expression Module applies quantitative real-time PCR (qPCR) with isoform-specific primers to measure UGT transcript levels, normalised to multiple reference genes, with amplification efficiencies between 95% and 105% and inter-run precision < 0.3 cycles. All modules are validated with reference UGT standards (e.g., recombinant UGT supersomes, pooled human liver microsomes) and include rigorous quality controls (system suitability, blank subtraction, and replicate analyses).

Unmatched Sensitivity, Specificity, and Mechanistic Insight

Our platform consistently delivers performance that surpasses typical industry standards. In activity assays, we achieve signal-to-noise ratios > 200:1 at LOD, and our kinetic fitting software uses global non-linear regression to provide precise estimates of K_m and V_max, with residual errors < 3%. For protein quantitation by PRM, our chromatographic gradient resolves isoform-specific peptides with retention time reproducibility < 0.5% RSD and peak area precision < 4%. In inhibition studies, we perform full dose-response curves with at least 8 concentrations in triplicate, and we provide Dixon plots and Cornish-Bowden analyses to determine the mechanism of inhibition. Additionally, we offer spectral analysis of UGT activity using fluorescence and UV-Vis spectroscopy to detect unexpected metabolic pathways. For clients requiring in-depth mechanistic studies, we provide kinetic modelling of glucuronidation that accounts for substrate inhibition, allosteric activation, and cooperative binding. This multi-dimensional data set enables our clients to not only quantify UGT activity but also to understand the underlying kinetics, the impact of genetic variants, and the potential for drug interactions, facilitating informed decisions in drug development and clinical practice.

Distinctive Advantages of Our UGT Detection Service

Our service provides several unique benefits that directly address client challenges. First, we have developed matrix-specific sample preparation protocols for a wide variety of UGT sources—including recombinant enzymes, human and animal liver microsomes, intestinal microsomes, kidney microsomes, cultured hepatocytes, and tissue homogenates—that effectively preserve enzyme activity and protein integrity, achieving recoveries > 95% for all tested matrices. Second, we maintain a comprehensive reference library of UGT isoforms and their characterised probe substrates, inhibitors, and inducers, enabling rapid method setup and benchmarking. Third, we offer a rapid screening service using a fluorogenic substrate cocktail assay that provides semi-quantitative activity data for multiple UGT isoforms within 4 hours of sample receipt—ideal for hit identification, lead optimisation, and early DDI assessment. Fourth, our customised drug interaction studies can be tailored to simulate clinically relevant concentrations, including the use of physiologically-based pharmacokinetic (PBPK) modelling to predict the magnitude of DDI. Fifth, we provide integrated data interpretation that links UGT activity, protein abundance, and genotype (if provided) to clinical outcomes, enabling clients to prioritise compounds with favourable clearance and interaction profiles. Sixth, all our methods comply with ICH M10, FDA, and EMA guidelines on drug metabolism and bioanalytical method validation, and we supply full validation dossiers (specificity, linearity, accuracy, precision, LOD, LOQ, robustness) along with detailed SOPs, ensuring that our data are readily accepted by global regulatory authorities. Our team of pharmacologists, enzymologists, and mass spectrometrists provides consultative interpretation, helping clients to design follow-up experiments, predict in vivo clearance, and support regulatory submissions.

Advanced Data Integration, Predictive Modeling, and Reporting

Our reporting transforms analytical data into strategic decision-making knowledge. We deliver a comprehensive final report that includes: (i) an executive dashboard with key metrics (specific activity, K_m, CL_int, IC₅₀, protein abundance) presented as concise scorecards; (ii) a detailed analytical section containing raw data, calibration curves, chromatograms, and kinetic fits; (iii) a statistical comparison of samples against reference standards or historical data, with p-values and confidence intervals; and (iv) an interpretive narrative that contextualises the results—for example, explaining how a high intrinsic clearance may translate to a low oral bioavailability, or how a low IC₅₀ value indicates a strong potential for drug-drug interaction. For clients with multiple compounds or donor samples, we provide multivariate analysis (PCA, PLS-DA) to identify the most influential parameters and to guide compound selection. We also offer predictive models that estimate hepatic clearance or DDI risk based on in vitro UGT data, using our internally developed PBPK modelling tools. All raw data files (e.g., .xlsx, .raw, .cdf) are supplied to ensure full transparency and re-analysis capability.

Broad Applications Across Drug Discovery, Clinical Pharmacology, and Toxicological Sciences

The versatility of our UGT detection service spans a wide range of sectors. In pharmaceutical and biotech R&D, our assays are critical for lead optimisation, candidate selection, and DDI risk assessment. In clinical pharmacology and therapeutic drug monitoring, our quantification of UGT activity in patient samples supports personalised dosing and pharmacogenomic studies. In environmental and occupational toxicology, UGT activity is used as a biomarker of exposure to certain xenobiotics. In academic research, our detailed kinetic and proteomic data support publication-quality studies on enzyme regulation and inter-individual variability. In contract research organisations (CROs), our services provide robust data to support regulatory submissions. In quality control of biological products, we verify the activity of UGT enzymes used in commercial assay kits and reference materials. Our ability to tailor the analytical package to the specific enzyme source, substrate class, and regulatory framework ensures that we serve a diverse global clientele with scientific rigour and practical relevance.

Commitment to Innovation, Quality, and Client Partnership

We are dedicated to advancing UGT analytics through continuous technological improvement. Our current R&D includes the development of high-content, multiplexed activity assays using microfluidic chips for simultaneous measurement of multiple isoforms, and the application of machine learning algorithms to predict DDI risk from chemical structure. We actively participate in inter-laboratory proficiency testing for drug metabolism studies and contribute to the development of reference standards for UGT activity. Our quality management system is ISO 9001 and ISO 17025 certified, and we follow GLP for all regulatory studies. We offer flexible engagement models—from single‑sample analysis to multi‑year collaborative projects—with dedicated project managers, volume discounts, and priority handling for time‑sensitive samples. Our global logistics provide specialised shipping kits (with stabilising buffers and temperature control) to preserve enzyme activity during transit. Turnaround times range from 2 business days for rapid screening to 12 business days for comprehensive kinetic, inhibition, and proteomic profiling. We maintain open communication, providing preliminary results upon request and final reports with expert commentary. Our success is measured by the confidence our clients have in their data and their ability to advance drug development and clinical care. We invite you to partner with us to unlock the full potential of your UGT research.

In summary, our UGT detection service delivers a comprehensive, precise, and application‑oriented analytical solution that integrates enzyme activity, protein quantitation, inhibition profiling, and gene expression. By combining advanced instrumentation with deep expertise in drug metabolism, we empower our clients to optimise drug candidates, assess safety, and advance personalised medicine. We look forward to supporting your UGT analysis needs with our state‑of‑the‑art analytical platform.